Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 23, 2025 • 1:00 AM ET

Date/Time Source News Release
12/16/2024 07:00 AM EST GlobeNewswire Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
09/19/2024 07:00 AM EDT GlobeNewswire Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
08/27/2024 08:00 AM EDT GlobeNewswire Larimar Therapeutics to Participate in Upcoming Investor Conferences
08/07/2024 07:00 AM EDT GlobeNewswire Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
05/30/2024 04:05 PM EDT GlobeNewswire Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
05/20/2024 04:05 PM EDT GlobeNewswire Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
05/09/2024 07:00 AM EDT GlobeNewswire Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
03/14/2024 04:05 PM EDT GlobeNewswire Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
03/11/2024 04:05 PM EDT GlobeNewswire Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia
03/06/2024 04:05 PM EST GlobeNewswire Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Page

Additional News

As of January 23, 2025 • 1:00 AM ET

Date/Time Source News Release
01/21/2025 06:27 PM EST SeekingAlpha Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
01/08/2025 10:24 AM EST Zacks SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
01/07/2025 05:23 PM EST SeekingAlpha Solid Biosciences stock jumps 11% post-market on FDA update
01/03/2025 05:49 PM EST SeekingAlpha Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
12/17/2024 09:14 AM EST KlickAnalytics LRMR Price Target Alert: $15.00. Issued by H.C. Wainwright
12/17/2024 07:00 AM EST KlickAnalytics Buy Recommendation Issued On LRMR By H.C. Wainwright
11/27/2024 04:31 AM EST US Earnings Reports Expected earnings - Larimar Therapeutics Inc.
11/20/2024 03:31 PM EST SeekingAlpha Q3 2024 Earnings: Hold Akebia Therapeutics
10/03/2024 11:26 AM EDT SeekingAlpha Larimar started at outperform by Wedbush on FA drug candidate
10/03/2024 09:59 AM EDT KlickAnalytics LRMR Price Target Alert: $22.00. Issued by Wedbush
Page